Drug intelligence / Profile preview

isovanillin

Development stage
Preclinical
Modality
Small Molecules
Administration
Oral
01

Overview

Isovanillin is a **phenolic aldehyde** and organic compound structurally related to vanillin. It is a selective **inhibitor of aldehyde oxidase** and is not a substrate for this enzyme[1][2][7]. Isovanillin is metabolized by **aldehyde dehydrogenase** to form isovanillic acid[1][2]. It has shown potential as an antidiarrhoeal and antispasmodic agent in animal studies, apparently by reducing gastrointestinal motility, though its precise mechanism in the GI tract is not fully determined[3][7]. Isovanillin is also a precursor in the chemical synthesis of morphine and other compounds such as combretastatin A-4[2][7]. Other reported bioactivities include antifungal, antioxidant, and free-radical scavenging effects[7][9]. There is no evidence of commercial development as a human pharmaceutical; research has explored its use in alcohol aversion therapy and as an antidiarrhoeal drug[1][2][3][7].

Other names
isovanillin3-hydroxy-4-methoxybenzaldehydebenzaldehyde 3-hydroxy-4-methoxybenzaldehyde3-hydroxy-4-methoxybenzaldehyde-3-hydroxy-4-methoxyiso-vanillinisovanilline5-formylguaiacol3-hydroxy-p-anisaldehyde3-hydroxyanisaldehyde4-methoxy-3-hydroxybenzaldehyde3-hydroxy-4-anisaldehydeoxy-3 methoxy-4 benzaldehydeoxy3 methoxy-4 benzaldehydeoxy 3 methoxy-4 benzaldehydeisovanicalinep-anisaldehyde 3-hydroxyp-anisaldehyde3-hydroxyp-anisaldehyde-3-hydroxy3-hydroxy-4-methoxy benzaldehyde5-formyl-2-methoxyphenolNSC 82996NSC82996NSC-82996
02

Targets

ALDH1A1 (Aldehyde dehydrogenase 1 family member A1)AOX1 (Aldehyde oxidase 1)

Beyond the preview

Go deeper on isovanillin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on isovanillin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call